Payment overview · 2025
General Payments
$719.71
23 reported records · 8 companies
Healthcare provider profile · identity verified
Oliver M Burrows, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GLENDORA, CA · NPI 1033157979
Verified facts
What the public records show
CMS Open Payments records show Oliver M Burrows, M.D. received $719.71 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $307.15 | 42.7% | 7 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $171.08 | 23.8% | 9 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $75.14 | 10.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.19 | 8.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.79 | 4.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.37 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.07 | 3.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.92 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $719.71 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $307.15 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $193.76 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $171.08 | 9 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $75.14 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $32.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.07 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 508 | 146 |
| Losartan Potassium | Losartan Potassium | 377 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 96 |
| Metformin Hcl | Metformin Hcl | 318 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 251 | 79 |
| Azithromycin | Azithromycin | 176 | 132 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 51 |
| Gabapentin | Gabapentin | 169 | 60 |
| Trazodone Hcl | Trazodone Hcl | 166 | 57 |
| Alprazolam | Alprazolam | 158 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 150 | 51 |
| Furosemide | Furosemide | 141 | 46 |
| Omeprazole | Omeprazole | 136 | 45 |
| Glipizide Er | Glipizide | 124 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 103 | 31 |
| Atenolol | Atenolol | 87 | 23 |
| Fenofibrate | Fenofibrate,micronized | 84 | 27 |
| Ibuprofen | Ibuprofen | 83 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 22 |
| Methylprednisolone | Methylprednisolone | 82 | 65 |
| Synthroid | Levothyroxine Sodium | 78 | 20 |
| Eliquis | Apixaban | 77 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 24 |
| Tramadol Hcl | Tramadol Hcl | 71 | 28 |
| Amoxicillin | Amoxicillin | 67 | 64 |
| Glipizide | Glipizide | 66 | 22 |
| Lorazepam | Lorazepam | 66 | 16 |
| Jardiance | Empagliflozin | 62 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 24 |
| Potassium Chloride | Potassium Chloride | 60 | 20 |
| Terazosin Hcl | Terazosin Hcl | 59 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 17 |
| Ezetimibe | Ezetimibe | 54 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 15 |
| Ketoconazole | Ketoconazole | 53 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 21 |
| Montelukast Sodium | Montelukast Sodium | 50 | 17 |
| Naproxen | Naproxen | 49 | 20 |
| Benazepril Hcl | Benazepril Hcl | 48 | 12 |
| Meloxicam | Meloxicam | 47 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 13 |
| Finasteride | Finasteride | 44 | 11 |
| Sertraline Hcl | Sertraline Hcl | 42 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | 14 |
| Allopurinol | Allopurinol | 40 | 14 |
| Cephalexin | Cephalexin | 40 | 35 |
| Famotidine | Famotidine | 37 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 36 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 14 |
| Telmisartan | Telmisartan | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 21 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | 12 |
| Donepezil Hcl | Donepezil Hcl | 32 | 12 |
| Carvedilol | Carvedilol | 31 | suppressed |
| Prednisone | Prednisone | 31 | 19 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | 16 |
| Clarithromycin | Clarithromycin | 26 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Triazolam | Triazolam | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 11 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $719.71 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, Cologuard Collection Kit, KRYSTEXXA, LifeVest, NURTEC ODT, ZAVZPRET, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error